Literature DB >> 26967221

Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.

Antonella Tramutola1, Gilda Pupo1, Fabio Di Domenico1, Eugenio Barone1,2, Andrea Arena1, Chiara Lanzillotta1, Diede Brokeaart3, Carla Blarzino1, Elizabeth Head4, D Allan Butterfield4,5, Marzia Perluigi1.   

Abstract

Down syndrome (DS) is the most common genetic cause of intellectual disability, resulting from trisomy of chromosome 21. The main feature of DS neuropathology includes early onset of Alzheimer's disease (AD), with deposition of senile plaques and tangles. We hypothesized that apoptosis may be activated in the presence of AD neuropathology in DS, thus we measured proteins associated with upstream and downstream pathways of p53 in the frontal cortex from DS cases with and without AD pathology and from Ts65Dn mice, at different ages. We observed increased acetylation and phosphorylation of p53, coupled to reduced MDM2/p53 complex level and lower levels of SIRT1. Activation of p53 was associated with a number of targets (BAX, PARP1, caspase-3, p21, heat shock proteins, and PGC1α) that were modulated in both DS and DS/AD compared with age-matched controls. In particular, the most relevant changes (increased p-p53 and acetyl-p53 and reduced formation of MDM2/p53 complex) were found to be modified only in the presence of AD pathology in DS. In addition, a similar pattern of alterations in the p53 pathway was found in Ts65Dn mice. These results suggest that p53 may integrate different signals, which can result in a pro-apoptotic-phenotype contributing to AD neuropathology in people with DS.

Entities:  

Keywords:  Apoptosis; Ts65Dn mouse model; caspase; p53; sirtuins; trisomy 21

Mesh:

Substances:

Year:  2016        PMID: 26967221      PMCID: PMC4968087          DOI: 10.3233/JAD-151105

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  66 in total

Review 1.  The brain in Down syndrome.

Authors:  R Seidl; N Cairns; G Lubec
Journal:  J Neural Transm Suppl       Date:  2001

2.  Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.

Authors:  S Nakamura; J A Roth; T Mukhopadhyay
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn.

Authors:  Laura G Reinholdt; Yueming Ding; Griffith J Gilbert; Griffith T Gilbert; Anne Czechanski; Jeffrey P Solzak; Randall J Roper; Mark T Johnson; Leah Rae Donahue; Cathleen Lutz; Muriel T Davisson
Journal:  Mamm Genome       Date:  2011-09-28       Impact factor: 2.957

4.  Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death.

Authors:  C Stadelmann; T L Deckwerth; A Srinivasan; C Bancher; W Brück; K Jellinger; H Lassmann
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

Review 5.  Unfolded p53: a potential biomarker for Alzheimer's disease.

Authors:  Cristina Lanni; Daniela Uberti; Marco Racchi; Stefano Govoni; Maurizio Memo
Journal:  J Alzheimers Dis       Date:  2007-08       Impact factor: 4.472

Review 6.  p53 and mitochondrial function in neurons.

Authors:  David B Wang; Chizuru Kinoshita; Yoshito Kinoshita; Richard S Morrison
Journal:  Biochim Biophys Acta       Date:  2014-01-08

Review 7.  p53 ubiquitination: Mdm2 and beyond.

Authors:  Christopher L Brooks; Wei Gu
Journal:  Mol Cell       Date:  2006-02-03       Impact factor: 17.970

Review 8.  Beta-amyloid, oxidative stress and down syndrome.

Authors:  Ira T Lott; Elizabeth Head; Eric Doran; Jorge Busciglio
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

9.  Apoptosis in Down's syndrome: lessons from studies of human and mouse models.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Apoptosis       Date:  2013-02       Impact factor: 4.677

10.  PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.

Authors:  Weiping Qin; Vahram Haroutunian; Pavel Katsel; Christopher P Cardozo; Lap Ho; Joseph D Buxbaum; Giulio M Pasinetti
Journal:  Arch Neurol       Date:  2009-03
View more
  10 in total

Review 1.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

Review 2.  Synthetic combinations of missense polymorphic genetic changes underlying Down syndrome susceptibility.

Authors:  Rebecca A Jackson; Mai Linh Nguyen; Angela N Barrett; Yuan Yee Tan; Mahesh A Choolani; Ee Sin Chen
Journal:  Cell Mol Life Sci       Date:  2016-05-31       Impact factor: 9.261

3.  Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models.

Authors:  Chiara Lanzillotta; Antonella Tramutola; Shelby Meier; Frederick Schmitt; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico; Jose F Abisambra
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 4.  Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.

Authors:  Antonella Tramutola; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Alessandra Giorgi; Laura di Francesco; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Antioxid Redox Signal       Date:  2016-10-26       Impact factor: 8.401

Review 5.  Oxidative Stress, Amyloid-β Peptide, and Altered Key Molecular Pathways in the Pathogenesis and Progression of Alzheimer's Disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules.

Authors:  Chiara Lanzillotta; Fabio Di Domenico
Journal:  Biomolecules       Date:  2021-02-11

7.  MicroRNA-668-3p regulates oxidative stress and cell damage induced by Aβ1-42 by targeting the OXR1/p53-p21 axis.

Authors:  Shengyu Li; Lishuo Wu; Meigang Ma; Longxiu Yang; Chao Qin
Journal:  Ann Transl Med       Date:  2022-09

8.  Chronic MK-801 Application in Adolescence and Early Adulthood: A Spatial Working Memory Deficit in Adult Long-Evans Rats But No Changes in the Hippocampal NMDA Receptor Subunits.

Authors:  Libor Uttl; Tomas Petrasek; Hilal Sengul; Marketa Svojanovska; Veronika Lobellova; Karel Vales; Dominika Radostova; Grygoriy Tsenov; Hana Kubova; Anna Mikulecka; Jan Svoboda; Ales Stuchlik
Journal:  Front Pharmacol       Date:  2018-02-12       Impact factor: 5.810

Review 9.  Down Syndrome, Obesity, Alzheimer's Disease, and Cancer: A Brief Review and Hypothesis.

Authors:  Daniel W Nixon
Journal:  Brain Sci       Date:  2018-03-24

Review 10.  Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome.

Authors:  Carmen Martínez-Cué; Noemí Rueda
Journal:  Int J Mol Sci       Date:  2020-09-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.